Skip to content
Erudio Health
menu
Clinical trial · no report yet · Phase 1

NCT05936359

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Preliminary discovery

Commentary in our index that names this trial so far

Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.

ChannelFound
Bluesky threads2
X threads1

The trial

ClinicalTrials.gov
Official title
A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Phase
Phase 1
Status
Active, not recruiting
Conditions
Myeloproliferative Neoplasms
Interventions
INCA033989; Ruxolitinib
Arms
  • Part 1a Dose Escalation Cohort Disease Group A - with MF · Experimental
  • Part 1a Dose Escalation Cohort Disease Group A - with ET · Experimental
  • Part 1a: Dose Escalation Cohort Disease Group B - with TGB-MF SubOpt R · Experimental
  • Part 1b: Dose Expansion - with MF · Experimental
  • Part 1b: Dose Expansion - with TGB-MF SubOpt R · Experimental
  • Part 1b: Dose Expansion - with ET · Experimental
  • Part 1c: Dose Expansion · Experimental
Enrollment
160
Primary outcomes
  • Number of participants with Dose Limiting Toxicities (DLTs)
  • Number of participants with Treatment-emergent Adverse Events (TEAEs)
  • Number of participants with TEAEs leading to dose modification or discontinuation
Sponsor
Incyte Corporation
Start
Sep 25, 2023
Primary completion
Feb 29, 2028 (estimated)
Results posted
No
Registry record
NCT05936359 · updated Aug 10, 2026